Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant
Lendava Biologics Facility Is Expected To Become Fully Operational By 2026
Executive Summary
Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.
You may also be interested in...
Sandoz, Accord Confirm First US Aubagio Generics, As Settlement Day Arrives
Viatris’ Mylan and Teva are among firms holding approved ANDAs for generic Aubagio, as the product falls to generic competition in the US.
Sandoz Chief Looks To Build On Recent Deals
With a number of recent deals under the firm’s belt in both generics and biosimilars, Sandoz CEO Richard Saynor talks to Generics Bulletin about how the firm is integrating new assets and building towards some key launches this year.
Sandoz Gets EU Nod For Higher-Strength Adalimumab
Sandoz has received a positive opinion from the EMA’s CHMP recommending that its high-concentration 100mg/ml adalimumab biosimilar be granted a pan-European marketing authorization. Three generics were also endorsed at the CHMP’s January meeting, including a rival to Forxiga.